{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:29:12Z","timestamp":1790404152928,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T00:00:00Z","timestamp":1487116800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T00:00:00Z","timestamp":1487116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI-43346"],"award-info":[{"award-number":["R01 AI-43346"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s11095-017-2121-7","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T17:37:56Z","timestamp":1487180276000},"page":"1115-1124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation"],"prefix":"10.1007","volume":"34","author":[{"given":"Celeste","family":"Alvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Andes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Yeon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen S.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,15]]},"reference":[{"issue":"4","key":"2121_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/cid\/civ1194","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of america. Clin Infect Dis. 2016;62(4):409\u201317.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2121_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3181\/00379727-138-35943","volume":"138","author":"G Medoff","year":"1971","unstructured":"Medoff G, Comfort M, Kobayashi GS. Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc Soc Exp Biol Med. 1971;138(2):571.","journal-title":"Proc Soc Exp Biol Med"},{"issue":"1","key":"2121_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/infdis\/132.1.82","volume":"132","author":"JZ Montgomerie","year":"1975","unstructured":"Montgomerie JZ, Edwards JE, Guze LB. Synergism of amphotericin B and 5-fluorocytosine for Candida species. J Infect Dis. 1975;132(1):82\u20136.","journal-title":"J Infect Dis"},{"issue":"5","key":"2121_CR4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1128\/AAC.22.5.763","volume":"22","author":"FC Odds","year":"1982","unstructured":"Odds FC. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother. 1982;22(5):763\u201370.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7\u20138","key":"2121_CR5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1439-0507.1991.tb00663.x","volume":"34","author":"GM Scalarone","year":"1991","unstructured":"Scalarone GM, Mikami Y, Kurita N, Ichihara Y, Yazawa K, Miyaji M. Turbidometric characterization of the postantifungal effect - Comparative studies with amphotericin B, 5-fluorocytosine and miconazole on Candida albicans. Mycoses. 1991;34(7\u20138):297\u2013302.","journal-title":"Mycoses"},{"issue":"3","key":"2121_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/BF00436389","volume":"120","author":"GM Scalarone","year":"1992","unstructured":"Scalarone GM, Mikami Y, Kurita N, Yazawa K, Miyaji M. Comparative studies on the postantifungal effect produced by the synergistic interaction of flucytosine and amphotericin B on Candida albicans. Mycopathologia. 1992;120(3):133\u20138.","journal-title":"Mycopathologia"},{"issue":"3","key":"2121_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.7326\/0003-4819-113-3-183","volume":"113","author":"RA Larsen","year":"1990","unstructured":"Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS - A randomized trial. Ann Intern Med. 1990;113(3):183\u20137.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2121_CR8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/0002-9343(87)90691-7","volume":"83","author":"AM Stamm","year":"1987","unstructured":"Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med. 1987;83(2):236\u201342.","journal-title":"Am J Med"},{"issue":"3","key":"2121_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.7326\/0003-4819-86-3-319","volume":"86","author":"JE Bennett","year":"1977","unstructured":"Bennett JE. Flucytosine. Ann Intern Med. 1977;86(3):319\u201322.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2121_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1128\/CMR.18.1.163-194.2005","volume":"18","author":"PK Mukherjee","year":"2005","unstructured":"Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA. Combination treatment of invasive fungal infections. Clin Microbiol Rev. 2005;18(1):163\u201394.","journal-title":"Clin Microbiol Rev"},{"issue":"7","key":"2121_CR11","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1073\/pnas.1117280109","volume":"109","author":"KC Gray","year":"2012","unstructured":"Gray KC, Palacios DS, Dailey I, Endo MM, Uno BE, Wilcock BC, et al. Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci U S A. 2012;109(7):2234\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2121_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1073\/pnas.69.1.196","volume":"69","author":"G Medoff","year":"1972","unstructured":"Medoff G, Kobayash GS, Venkov P, Schlessi D, Kwan CN. Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B. Proc Natl Acad Sci U S A. 1972;69(1):196\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2121_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000238101","volume":"28","author":"WH Beggs","year":"1982","unstructured":"Beggs WH, Sarosi GA. Further evidence for sequential action of amphotericin B and 5-fluorocytosine against Candida albicans. Chemotherapy. 1982;28(5):341\u20134.","journal-title":"Chemotherapy"},{"issue":"1","key":"2121_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1128\/AAC.29.1.44","volume":"29","author":"BE Harris","year":"1986","unstructured":"Harris BE, Manning BW, Federle TW, Diasio RB. Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrob Agents Chemother. 1986;29(1):44\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1\u20132","key":"2121_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000069784","volume":"49","author":"A Vermes","year":"2003","unstructured":"Vermes A, Kuijper EJ, Guchelaar HJ, Dankert J. An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora. Chemotherapy. 2003;49(1\u20132):17\u201323.","journal-title":"Chemotherapy"},{"issue":"1","key":"2121_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1046\/j.1472-8206.2002.00064.x","volume":"16","author":"A Vermes","year":"2002","unstructured":"Vermes A, Guchelaar HJ, van Kuilenburg ABP, Dankert J. 5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study. Fundam Clin Pharmacol. 2002;16(1):39\u201347.","journal-title":"Fundam Clin Pharmacol"},{"issue":"10","key":"2121_CR17","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1128\/AAC.36.10.2310","volume":"36","author":"J Barwicz","year":"1992","unstructured":"Barwicz J, Christian S, Gruda I. Effects of the aggregation state of amphotericin B on its toxicity to mice. Antimicrob Agents Chemother. 1992;36(10):2310\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2121_CR18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1086\/319211","volume":"32","author":"DW Bates","year":"2001","unstructured":"Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DRJ, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001;32(5):686\u201393.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2121_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1086\/376634","volume":"37","author":"L Ostrosky-Zeichner","year":"2003","unstructured":"Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: Time for a new \u201cgold standard\u201d. Clin Infect Dis. 2003;37(3):415\u201325.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2121_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/clinids\/12.2.308","volume":"12","author":"HA Gallis","year":"1990","unstructured":"Gallis HA, Drew RH, Pickard WW. Amphotericin-B - 30\u00a0years of clinical experience. Rev Infect Dis. 1990;12(2):308\u201329.","journal-title":"Rev Infect Dis"},{"issue":"3","key":"2121_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1139\/o88-024","volume":"66","author":"I Gruda","year":"1988","unstructured":"Gruda I, Dussault N. Effect of the aggregation state of amphotericin B on its interaction with ergosterol. Biochem Cell Biol. 1988;66(3):177\u201383.","journal-title":"Biochem Cell Biol"},{"issue":"1","key":"2121_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1128\/AAC.35.1.24","volume":"35","author":"I Gruda","year":"1991","unstructured":"Gruda I, Milette D, Brother M, Kobayashi GS, Medoff G, Brajtburg J. Structure-activity study of inhibition of amphotericin B (Fungizone) binding to sterols, toxicity to cells, and lethality to mice by esters of sucrose. Antimicrob Agents Chemother. 1991;35(1):24\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2121_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/0005-2736(90)90305-8","volume":"1030","author":"P Tancrede","year":"1990","unstructured":"Tancrede P, Barwicz J, Jutras S, Gruda I. The effect of surfactants on the aggregation state of amphotericin B. Biochim Biophys Acta. 1990;1030(2):289\u201395.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"2121_CR24","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/jps.22445","volume":"100","author":"TA Diezi","year":"2011","unstructured":"Diezi TA, Takemoto JK, Davies NM, Kwon GS. Pharmacokinetics and nephrotoxicity of amphotericin B-incorporated poly(ethylene glycol)-block-poly(n-hexyl stearate L-aspartamide) micelles. J Pharm Sci. 2011;100(6):2064\u201370.","journal-title":"J Pharm Sci"},{"issue":"1\u20133","key":"2121_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0168-3659(98)00095-9","volume":"56","author":"BG Yu","year":"1998","unstructured":"Yu BG, Okano T, Kataoka K, Sardari S, Kwon GS. In vitro dissociation of antifungal efficacy and toxicity for amphotericin B-loaded poly(ethylene oxide)-block-poly(beta-benzyl-L-aspartate) micelles. J Control Release. 1998;56(1\u20133):285\u201391.","journal-title":"J Control Release"},{"issue":"11","key":"2121_CR26","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1001\/archinte.1988.00380110049010","volume":"148","author":"RA Branch","year":"1988","unstructured":"Branch RA. Prevention of amphotericin B induced renal impairment - A review on the use of sodium supplementation. Arch Intern Med. 1988;148(11):2389\u201394.","journal-title":"Arch Intern Med"},{"issue":"2","key":"2121_CR27","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/ki.1991.214","volume":"40","author":"A Llanos","year":"1991","unstructured":"Llanos A, Cieza J, Bernardo J, Echevarria J, Biaggioni I, Sabra R, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int. 1991;40(2):302\u20138.","journal-title":"Kidney Int"},{"issue":"9","key":"2121_CR28","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s11095-016-1948-7","volume":"33","author":"C Alvarez","year":"2016","unstructured":"Alvarez C, Shin DH, Kwon GS. Reformulation of fungizone by PEG-DSPE micelles: deaggregation and detoxification of amphotericin B. Pharm Res. 2016;33(9):2098\u2013106.","journal-title":"Pharm Res"},{"issue":"1","key":"2121_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/0005-2736(80)90074-7","volume":"599","author":"J Bolard","year":"1980","unstructured":"Bolard J, Seigneuret M, Boudet G. Interaction between phospholipid-bilayer membranes and the polyene antibiotic amphotericin B - lipid state and cholesterol content dependence. Biochim Biophys Acta. 1980;599(1):280\u201393.","journal-title":"Biochim Biophys Acta"},{"issue":"7\u20138","key":"2121_CR30","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1046\/j.1439-0507.1999.00498.x","volume":"42","author":"R Franz","year":"1999","unstructured":"Franz R, Ruhnke M, Morschhauser J. Molecular aspects of fluconazole resistance development in Candida albicans. Mycoses. 1999;42(7\u20138):453\u20138.","journal-title":"Mycoses"},{"issue":"8","key":"2121_CR31","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1128\/AAC.40.8.1914","volume":"40","author":"RL White","year":"1996","unstructured":"White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: Time-kill, checkerboard, and E test. Antimicrob Agents Chemother. 1996;40(8):1914\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2121_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1128\/AAC.46.1.245-247.2002","volume":"46","author":"S Arikan","year":"2002","unstructured":"Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother. 2002;46(1):245\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2121_CR33","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1128\/AAC.42.5.1207","volume":"42","author":"ME Klepser","year":"1998","unstructured":"Klepser ME, Ernst EJ, Lewis RE, Ernst ME, Pfaller MA. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob Agents Chemother. 1998;42(5):1207\u201312.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2121_CR34","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1128\/AAC.49.4.1593-1596.2005","volume":"49","author":"E Canton","year":"2005","unstructured":"Canton E, Peman J, Gobernado M, Viudes A, Espinel-Ingroff A. Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob Agents Chemother. 2005;49(4):1593\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2121_CR35","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1128\/AAC.45.3.922-926.2001","volume":"45","author":"D Andes","year":"2001","unstructured":"Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother. 2001;45(3):922\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2121_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jac\/dkm389","volume":"61","author":"ML Goodwin","year":"2008","unstructured":"Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother. 2008;61(1):17\u201325.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2121_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1128\/AAC.00705-08","volume":"53","author":"D Andes","year":"2009","unstructured":"Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53(1):24\u201334.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2121_CR38","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/jac\/dkl550","volume":"59","author":"AC Pasqualotto","year":"2007","unstructured":"Pasqualotto AC, Howard SJ, Moore CB, Denning DW. Flucytosine therapeutic monitoring: 15\u00a0years experience from the UK. J Antimicrob Chemother. 2007;59(4):791\u20133.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2121_CR39","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1128\/AAC.01188-06","volume":"51","author":"AE Brouwer","year":"2007","unstructured":"Brouwer AE, van Kan HJM, Johnson E, Rajanuwong A, Teparrukkul P, Wuthiekanun V, et al. Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis. Antimicrob Agents Chemother. 2007;51(3):1038\u201342.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2121_CR40","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1128\/AAC.44.4.938-942.2000","volume":"44","author":"D Andes","year":"2000","unstructured":"Andes D, van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother. 2000;44(4):938\u201342.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2121_CR41","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.1128\/AAC.02394-12","volume":"57","author":"Z Steier","year":"2013","unstructured":"Steier Z, Vermitsky JP, Toner G, Gygax SE, Edlind T, Katiyar S. Flucytosine antagonism of azole activity versus Candida glabrata: role of transcription factor Pdr1 and multidrug transporter Cdr1. Antimicrob Agents Chemother. 2013;57(11):5543\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2121_CR42","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1002\/1520-6017(200012)89:12<1589::AID-JPS10>3.0.CO;2-6","volume":"89","author":"P Aramwit","year":"2000","unstructured":"Aramwit P, Bong GY, Lavasanifar A, Samuel J, Kwon GS. The effect of serum albumin on the aggregation state and toxicity of amphotericin B. J Pharm Sci. 2000;89(12):1589\u201393.","journal-title":"J Pharm Sci"},{"issue":"3","key":"2121_CR43","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1021\/bm0257614","volume":"4","author":"ML Adams","year":"2003","unstructured":"Adams ML, Andes DR, Kwon GS. Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity. Biomacromolecules. 2003;4(3):750\u20137.","journal-title":"Biomacromolecules"},{"issue":"7","key":"2121_CR44","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s11095-011-0626-z","volume":"29","author":"TA Diezi","year":"2012","unstructured":"Diezi TA, Kwon G. Amphotericin B\/sterol co-loaded peg-phospholipid micelles: effects of sterols on aggregation state and hemolytic activity of amphotericin B. Pharm Res. 2012;29(7):1737\u201344.","journal-title":"Pharm Res"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-017-2121-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-017-2121-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-017-2121-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T14:01:44Z","timestamp":1719064904000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-017-2121-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,15]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["2121"],"URL":"https:\/\/doi.org\/10.1007\/s11095-017-2121-7","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,15]]},"assertion":[{"value":"12 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}